2024
Modern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-escalationOutcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation
Su D, Rehman S, Wang K, Deng Y, Rose M, Dosani T, Kunstman J. Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation. Journal Of Surgical Research 2024, 301: 10-17. PMID: 38905768, DOI: 10.1016/j.jss.2024.04.033.Peer-Reviewed Original ResearchHematology consultationSingle-center retrospective studyClavien-Dindo classificationVA Connecticut Healthcare SystemAssess operative outcomesTime to resolutionPrimary outcome measureE-consultationOperative morbidityPostoperative transfusionHematologic complicationsSurgical outcomesNo significant differenceRetrospective studyProcedural dataOperative outcomesProcedural outcomesStudy cohortPatient characteristicsConsult volumeSecondary outcomesHematologic issuesAssociated with changesReferral patternsSurgeryMo1492 EFFECTS OF THE HEALTH INSURANCE MARKETPLACE ON GASTROINTESTINAL CANCER SURGERY OUTCOMES
Butensky S, Kerekes D, Bakkila B, Kurbatov V, Kunstman J, Billingsley K, Khan S. Mo1492 EFFECTS OF THE HEALTH INSURANCE MARKETPLACE ON GASTROINTESTINAL CANCER SURGERY OUTCOMES. Gastroenterology 2024, 166: s-1891. DOI: 10.1016/s0016-5085(24)04833-9.Peer-Reviewed Original ResearchProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original ResearchFactors associated with early mortalityCases of pancreatic adenocarcinomaPancreatic adenocarcinoma resectionRisk of early mortalityLength of stayEarly mortalityAdjuvant chemotherapyPancreatic adenocarcinomaChemotherapy utilizationAdenocarcinoma resectionRisk factors associated with early mortalityOmission of adjuvant therapyNon-metastatic pancreatic adenocarcinomaMultivariate Cox regression modelAssociated with early mortalityPost-resection survivalIncreased risk of early mortalityParticipant Use FileProlonged hospital stayProlonged length of stayAdjuvant chemotherapy utilizationDecrease perioperative complicationsCox regression modelsNon-academic centersHospital risk factors
2023
Effects of novel Coronavirus (COVID-19) on presentation, management, and outcomes of acute cholecystitis at an academic tertiary care center cholecystitis management during COVID-19
Peters N, O'Connor R, Bhattacharya B, Kunstman J. Effects of novel Coronavirus (COVID-19) on presentation, management, and outcomes of acute cholecystitis at an academic tertiary care center cholecystitis management during COVID-19. Heliyon 2023, 9: e22043. PMID: 38027854, PMCID: PMC10658381, DOI: 10.1016/j.heliyon.2023.e22043.Peer-Reviewed Original ResearchTertiary care centerAcute cholecystitisCare centerPersonal protective equipment (PPE) guidelinesAcademic tertiary care centerAcute surgical problemsNon-operative managementPre-operative testingCOVID-19 pandemicNon-significant trendCholecystitis patientsComplication rateStudy cohortOperative managementControl cohortCOVID cohortSurgical problemsRetrospective analysisSurgical carePatientsControl groupEquipment guidelinesCholecystitisAspects of healthcareCohortImpact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchGI cancer surgeryPreoperative chemotherapyCancer surgerySurgical careCOVID-19 pandemicCOVID-19Tertiary referral centerOncology patient populationFirst COVID-19 waveGI cancer casesCOVID-19 burdenHigh COVID-19 burdenEmergency surgeryReferral centerCOVID-19 waveOncology visitsGastrointestinal cancerGI cancersPatient populationStudy criteriaCancer careTreatment characteristicsCancer casesCase volumePatientsSurgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States
Kerekes D, Frey A, Bakkila B, Kunstman J, Khan S. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States. Journal Of Surgical Oncology 2023, 128: 790-802. PMID: 37435780, DOI: 10.1002/jso.27392.Peer-Reviewed Original ResearchConceptsGastroenteropancreatic neuroendocrine carcinomasGEP-NECSingle-site surgeryOverall survivalSurgical treatmentNeuroendocrine carcinomaMortality reductionSite surgeryPrimary siteNational Cancer DatabaseRetrospective cohort studyPrimary tumor typeSurgical resectionCohort studyAggressive diseaseSurgical interventionSurvival outcomesTreatment optionsCancer DatabaseSurgeryPatientsTumor typesNECStrongest predictorCarcinomaUtility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms
Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.Peer-Reviewed Original ResearchConceptsPapillary mucinous neoplasmMalignant risk stratificationCACNA1G geneRisk stratificationMucinous neoplasmsBiomarker panelBackgroundIntraductal papillary mucinous neoplasmIntraductal papillary mucinous neoplasmEarly detectionPrevious case-control studyHigh-grade dysplasiaCase-control studyPancreatic cancer precursorsReceiver Operating Characteristic (ROC) curve analysisSignificant diagnostic challengeCross-sectional imagingCharacteristic curve analysisOperating Characteristic curve analysisG geneHigh diagnostic specificityPrior validation studiesSignificant procedural riskIPMN tissuesSurgical resectionAdvanced neoplasia
2022
Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
Chhoda A, Sharma A, Tang H, Tan W, Sailo B, Peters N, Ying L, Ruzgar N, Kunstman J, Salem R, Farrell J, Ahuja N. Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. Gastroenterology 2022, 162: s-708. DOI: 10.1016/s0016-5085(22)61664-0.Peer-Reviewed Original ResearchTu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS
Singh S, Chhoda A, Vodusek Z, Khatri R, Gunderson C, McCarty T, Sharma P, Grimshaw A, Kunstman J, Sharma A, Ahuja N, Gonda T, Farrell J. Tu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2022, 162: s-907. DOI: 10.1016/s0016-5085(22)62148-6.Peer-Reviewed Original Research
2021
Sa298 IS IT SAFE TO STOP SURVEILLANCE OF PANCREATIC CYSTS AFTER 5 YEARS OF STABILITY?: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CURRENT EVIDENCE.
Chhoda A, Singh S, Sheth A, Sharma P, Sharma A, Kunstman J, Grimshaw A, Ahuja N, Farrell J. Sa298 IS IT SAFE TO STOP SURVEILLANCE OF PANCREATIC CYSTS AFTER 5 YEARS OF STABILITY?: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CURRENT EVIDENCE. Gastroenterology 2021, 160: s-475. DOI: 10.1016/s0016-5085(21)01841-2.Peer-Reviewed Original ResearchSa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSIS
Chhoda A, Singh S, Grimshaw A, Sheth A, Sharma A, Kunstman J, Ahuja N, Farrell J. Sa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2021, 160: s-477. DOI: 10.1016/s0016-5085(21)01845-x.Peer-Reviewed Original ResearchCystic Tumors Other than IPMN
Kunstman J, Farrell J. Cystic Tumors Other than IPMN. 2021, 608-623. DOI: 10.1002/9781119570097.ch74.Peer-Reviewed Original ResearchIntraductal papillary mucinous neoplasmMucinous cystic neoplasmCystic lesionsCystic neoplasmsCystic pancreatic endocrine neoplasmsNeoplastic cystic lesionsPapillary mucinous neoplasmSolid pseudopapillary neoplasmPancreatic endocrine neoplasmsPancreatic specialistsCystic tumorSurgical interventionMucinous neoplasmsCommon lesionsSerous cystadenomaPseudopapillary neoplasmEndocrine neoplasmsNeoplasmsClinical issuesLesionsNatural historyPancreasSuccessful managementLongitudinal seriesCystadenoma
2020
Comorbidities Drive the Majority of Overall Mortality in Low-Risk Mucinous Pancreatic Cysts Under Surveillance
Chhoda A, Yousaf MN, Madhani K, Aslanian H, Jamidar PA, Suarez AL, Salem R, Muniraj T, Kunstman J, Farrell JJ. Comorbidities Drive the Majority of Overall Mortality in Low-Risk Mucinous Pancreatic Cysts Under Surveillance. Clinical Gastroenterology And Hepatology 2020, 20: 631-640.e1. PMID: 33309984, DOI: 10.1016/j.cgh.2020.12.008.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexHigh-risk stigmataMucinous pancreatic cystsOverall mortalityWorrisome featuresPancreatic cystsComorbidity burdenAge-adjusted Charlson comorbidity indexKaplan-Meir survival analysisLow-risk cystsSingle-center studyHigher overall mortalityElectronic medical recordsComorbidity indexProspective surveillanceCenter studyMortality outcomesMedical recordsMucinous cystsPatient outcomesSerial imagingSurveillance populationCohort stratificationSurvival analysisAbstractTextS0106 Imaging Resource Utilization in the Surveillance of Presumed Branched Duct Intraductal Papillary Mucinous Neoplasm (BD-IPMN)
Yousaf M, Zhang Z, Chhoda A, Madhani K, Chaudhary F, Suarez A, Muniraj T, Kunstman J, Jamidar P, Aslanian H, Salem R, Farrell J. S0106 Imaging Resource Utilization in the Surveillance of Presumed Branched Duct Intraductal Papillary Mucinous Neoplasm (BD-IPMN). The American Journal Of Gastroenterology 2020, 115: s51-s51. DOI: 10.14309/01.ajg.0000702472.90174.1c.Peer-Reviewed Original ResearchS0116 Balancing Risks of Pancreatic Malignancy-Related and Non-Pancreatic-Related Mortality in Surveillance of Low-Risk Presumed Mucinous Pancreatic Cysts
Chhoda A, Madhani K, Yousuf M, Aslanian H, Jamidar P, Kunstman J, Salem R, Suarez A, Farrell J. S0116 Balancing Risks of Pancreatic Malignancy-Related and Non-Pancreatic-Related Mortality in Surveillance of Low-Risk Presumed Mucinous Pancreatic Cysts. The American Journal Of Gastroenterology 2020, 115: s56-s57. DOI: 10.14309/01.ajg.0000702512.87644.ef.Peer-Reviewed Original ResearchS0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database
Ilagan-Ying Y, Ying L, Ferrucci L, Peters N, Blackburn H, Kunstman J, Ahuja N. S0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database. The American Journal Of Gastroenterology 2020, 115: s48-s49. DOI: 10.14309/01.ajg.0000702452.53969.ae.Peer-Reviewed Original ResearchAssociation of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2019
Su1459 – Imaging Resource Utilization in Active Pancreatic Cyst Surveillance
Yousaf M, Zhang Z, Chhoda A, Madhani K, Suarez A, Muniraj T, Kunstman J, Jamidar P, Aslanian H, Salem R, Farrell J. Su1459 – Imaging Resource Utilization in Active Pancreatic Cyst Surveillance. Gastroenterology 2019, 156: s-559. DOI: 10.1016/s0016-5085(19)38287-3.Peer-Reviewed Original Research
2018
Outcomes after pancreatectomy with routine usage of pasireotide
Kunstman J, Goldman D, Gönen M, Balachandran V, DeMatteo R, D'Angelica M, Jarnagin W, Kingham T, Allen P. Outcomes after pancreatectomy with routine usage of pasireotide. Hepato Pancreato Biliary 2018, 20: s30. DOI: 10.1016/j.hpb.2018.02.061.Peer-Reviewed Original Research